Top Inhaled Nitric Oxide Companies

Global Inhaled Nitric Oxide Market size was valued at USD 1.29 Billion in 2024 and is poised to grow from USD 1.4 Billion in 2025 to USD 2.57 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026–2033). 

Several significant worldwide firms vying for market supremacy define the competitive landscape of the global inhaled nitric oxide market. To improve their position in the industry, major firms like Novoteris, Linde plc, Praxair Inc., Mallinckrodt Pharmaceuticals, and Air Liquide are actively working on new products, forming strategic alliances, and merging. To take advantage of the rising demand for inhaled nitric oxide therapy globally, these companies are concentrating on broadening their product offerings and geographic reach. 'Mallinckrodt Pharmaceuticals (United States) ', 'Air Liquide Healthcare (France) ', 'VERO Biotech (United States) ', 'Getinge AB (Sweden) ', 'Beyond Air, Inc. (United States) ', 'SLE Ltd. (United Kingdom) ', 'Bellerophon Therapeutics (United States) ', 'International Biomedical (United States) ', 'NIOX Group plc (United Kingdom) ', 'BOC Healthcare (United Kingdom) ', 'Merck KGaA (Germany) ', 'Nu-Med Plus Inc. (United States) ', 'Perma Pure LLC (United States) ', 'HALMA PLC (United Kingdom) ', 'Matheson Tri-Gas Inc. (United States) ', 'Circassia Pharmaceuticals (United Kingdom) ', 'International Biomedical (United States) '

The market for inhaled nitric oxide is significantly driven by the rising prevalence of respiratory illnesses. The need for inhaled nitric oxide as a therapy option is anticipated to increase if these disorders continue to impact many people globally. Exposure to air pollution, cigarette smoke, and occupational risks are examples of environmental contaminants that can have a substantial impact on respiratory health and raise the chance of acquiring respiratory disorders. The ageing population's weakening immune systems and inherent changes in lung function make them more vulnerable to respiratory diseases. It is anticipated that the prevalence of respiratory illnesses would increase as the world's population ages.

Growing Impact of Asthma and COPD: Among the most prevalent respiratory illnesses impacting the public are asthma and COPD, both of which can be fatal and impair a patient's daily ability to breathe. Chronic asthma is a disorder that causes the lungs' air passageways to expand and constrict, which results in attacks of dyspnea, bronchospasm, and reversible airflow blockage. A significant increase in cigarette usage exacerbates the symptoms of COPD and asthma. Furthermore, because of increased industrialization, there are now more occurrences of COPD and asthma, which could drive up demand for inhaled nitric oxide during the projection period.

Throughout the anticipated period, North America is anticipated to maintain its prominent position in the global inhaled nitric oxide market. This is since there are recognized organizations for research and development as well as a modern healthcare infrastructure. To deliver inhaled nitric oxide therapy, North America offers sophisticated healthcare facilities, including clinics and hospitals, as well as the knowledge and resources to do so. During the anticipated period, the inhaled nitric oxide market is expected to grow at the quickest rate in Europe. This is due to the presence of significant regional players, continuing research, and clinical trials regarding the safety and effectiveness of inhaled nitric oxide. In Europe, pulmonary hypertension is a prevalent ailment that impacts many people.